Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

Short name SURE FRANCE

NCTNCT04083820 (opens ClinicalTrials.gov in a new tab)Other idNN9535-4495Other idU1111-1222-5620
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase not stated
Enrollment
521 participants (actual)
Sponsor
Novo Nordisk A/S · Industry
Design
Not stated
Countries
1 country

France

Start
16 Sept 2019
Primary completion
27 Sept 2021
Completion
27 Sept 2021
First posted
10 Sept 2019
Last update posted
28 Mar 2023
Conditions
Diabetes Mellitus, Type 2

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2019202020212022
  1. Ph –

    SURE FRANCE

    NCT04083820

    16 Sept 2019 to 27 Sept 2021

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.

Interventions

  • semaglutideDrug

Arms1

  • Other

    Semaglutide s.c. once-weekly

    Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Change in Glycated Haemoglobin A1c (HbA1c)

    Time frame · Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)

    Registry description

    Measured in % point

  2. Change in Glycated Haemoglobin A1c (HbA1c)

    Time frame · Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)

    Registry description

    Measured in mmol/mol

Secondary outcomes(16)

  1. Change in body weight

    Time frame · Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)

    Registry description

    Measured in kg

  2. Change in body weight

    Time frame · Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)

    Registry description

    Measured in %

  3. Change in waist circumference

    Time frame · Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)

    Registry description

    Measured in cm

  4. HbA1c level below 8.0% (64 mmol/mol) (yes/no)

    Time frame · At end of study (week 28 to 38)

    Registry description

    Number of participants

  5. HbA1c level below 7.5% (59 mmol/mol) (yes/no)

    Time frame · At end of study (week 28 to 38)

    Registry description

    Number of participants

  6. HbA1c level below 7.0% (53 mmol/mol) (yes/no)

    Time frame · At end of study (week 28 to 38)

    Registry description

    Number of participants

  7. Reduction in HbA1c of 1.0% point or more (yes/no)

    Time frame · Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)

    Registry description

    Number of participants who achieved/not achieved reduction in HbA1c of 1.0% point or more

  8. Weight reduction of 3.0% or more (yes/no)

    Time frame · Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)

    Registry description

    Number of participants who achieved/not achieved weight reduction of 3.0% or more

  9. Weight reduction of 5.0% or more (yes/no)

    Time frame · Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)

    Registry description

    Number of participants who achieved/not achieved weight reduction of 5.0% or more

  10. HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)

    Time frame · Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)

    Registry description

    Number of participants who achieved/not achieved HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more

  11. Patient reported severe or documented hypoglycaemia (yes/no)

    Time frame · Between baseline (week 0), end of study (week 28-38)

    Registry description

    Number of participants

  12. Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction

    Time frame · Baseline (week 0), end of study (week 28 to 38)

    Registry description

    The status version (DTSQs) provides a measure of how satisfied patients are with their current diabetes treatment. It consists of 8 questions, which are to be answered on a Likert scale from 0 to 6 (0 = very dissatisfied to 6 = very satisfied). Six questions are summed to produce a total Treatment Satisfaction score. The remaining two questions are concerning perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia, respectively

  13. Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction

    Time frame · Baseline (week 0), end of study (week 28 to 38)

    Registry description

    The change version (DTSQc) has the same 8 items as the status version, but is reworded to direct the patients to compare the experience of the current treatment with the experience of previous treatment. Each question is scored on a scale of -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change

  14. Change in score for Short Form (SF)-36 v2: Physical summary component

    Time frame · Baseline (week 0), end of study (week 28 to 38)

    Registry description

    The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health).

  15. Change in score for SF-36 v2: Mental summary component

    Time frame · Baseline (week 0), end of study (week 28 to 38)

    Registry description

    The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health).

  16. Patient completed the study under treatment with semaglutide (yes/no)

    Time frame · At end of study (week 28 to 38)

    Registry description

    Number of participants

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Observational study · 2023

7 results

Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.

Mohammedi et al. 2023Diabetes, obesity & metabolismcited by 21

PMID 36869853DOI 10.1111/dom.15045PUB-36869853

Full text at the publisher7 results
Publisher pageSee results (7)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) * The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study * Male or female, age greater than or equal to 18 years at the time of signing informed consent * Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion * Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Treatment with any investigational drug within 90 days prior to enrolment into the study * Hypersensitivity to semaglutide or to any of the excipients

PepBank is a research reference. Talk to a doctor before you use any peptide.